In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
NeoRx STR 0303: a randomized multicenter study to compare the safety and efficacy of (166) HO-DOTMP plus melphalan to melphalan alone as conditioning for autologous peripheral blood stem cell transplant in subjects with primary refractory multiple myeloma.
Clapp
Kathleen
K
kclapp@neorx.com
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D019172:Transplantation Conditioning
D018906:Antineoplastic Agents, Alkylating; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C093387:holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid); D008558:Melphalan